Menegatti M, Vaira D, Miglioli M, Holton J, Vergura M R, Biasco G, Petronelli A, Ricci C, Azzarone P, Gusmaroli R
1st Medical Clinic, University of Bologna, Italy.
Am J Gastroenterol. 1995 Aug;90(8):1278-81.
To compare the seroprevalence of Helicobacter pylori in gastric and nongastric carcinoma patients and to investigate the relationship between H. pylori, gastric cancer site, and histological type.
In a 24-month period, 307 gastric cancer patients (male/female: 185/122; age range 19-94 yr, mean 69 yr) were investigated by serology (IgG to H. pylori), histology, and urease test for H. pylori. One hundred and seventy-seven gastric cancers were in the antrum, 98 were in the corpus, and 32 were in the fundus; 227 were intestinal and 80 were diffuse type. In the same study period, we assessed the H. pylori seroprevalence in 162 patients with nongastric carcinoma (lung n = 41, breast n = 42, genitourinary n = 41, GI tract n = 22, others n = 16) (male/female: 84/78; age range 31-81 yr, mean 56 yr).
The overall seroprevalence of H. pylori in gastric cancer and in nongastric cancer was 82 and 56%, respectively (p < 0.001). In asymptomatic blood donors (age range 55-65 yr) and in dyspeptic patients older than 60 yr, a seroprevalence of 55 and 58% was found, respectively, which is significantly lower (p > 0.001) than the gastric cancer patients but similar to the nongastric cancer population. No difference was found in the H. pylori status according to the gastric cancer site (83, 82, and 81% in the antrum, corpus, and fundus, respectively). Two hundred and twenty-seven gastric cancers [185 (81%) H. pylori-positive] were found to be of an intestinal type and 80 [66 (82%) H. pylori-positive] of a diffuse type (not significant). No age-related difference (below and above 60 yr) in H. pylori prevalence was observed within each cancer population, and, in both age groups, the seroprevalence of infection was higher in gastric cancer patients (86 and 81%) than in nongastric cancer patients (56 and 56%) (below and above 60 yr, respectively).
H. pylori seroprevalence is significantly higher in gastric cancer compared with nongastric cancer patients. No differences were observed in H. pylori seroprevalence according to gastric cancer site or histological type. The higher H. pylori seroprevalence in gastric cancer patients is not age related.
比较胃癌患者和非胃癌患者中幽门螺杆菌的血清阳性率，并研究幽门螺杆菌、胃癌部位和组织学类型之间的关系。
在24个月的时间里，对307例胃癌患者（男/女：185/122；年龄范围19 - 94岁，平均69岁）进行了血清学（抗幽门螺杆菌IgG）、组织学和幽门螺杆菌尿素酶试验检测。177例胃癌位于胃窦部，98例位于胃体部，32例位于胃底部；227例为肠型，80例为弥漫型。在同一研究期间，我们评估了162例非胃癌患者（肺癌41例，乳腺癌42例，泌尿生殖系统癌41例，胃肠道癌22例，其他癌16例）（男/女：84/78；年龄范围31 - 81岁，平均56岁）的幽门螺杆菌血清阳性率。
胃癌患者和非胃癌患者中幽门螺杆菌的总体血清阳性率分别为82%和56%（p < 0.001）。在无症状献血者（年龄范围55 - 65岁）和60岁以上的消化不良患者中，幽门螺杆菌血清阳性率分别为55%和58%，显著低于（p > 0.001）胃癌患者，但与非胃癌人群相似。根据胃癌部位，幽门螺杆菌感染状况无差异（胃窦部、胃体部和胃底部分别为83%、82%和81%）。227例胃癌[185例（81%）幽门螺杆菌阳性]为肠型，80例[66例（82%）幽门螺杆菌阳性]为弥漫型（无显著差异）。在每个癌症人群中，未观察到幽门螺杆菌感染率与年龄（60岁以下和60岁以上）相关的差异，并且在两个年龄组中，胃癌患者的感染血清阳性率（分别为60岁以下和60岁以上时为86%和81%）均高于非胃癌患者（分别为56%和56%）。
与非胃癌患者相比，胃癌患者中幽门螺杆菌的血清阳性率显著更高。根据胃癌部位或组织学类型，未观察到幽门螺杆菌血清阳性率的差异。胃癌患者中较高的幽门螺杆菌血清阳性率与年龄无关。
